Trombopag 50mg Tablet

Trombopag 50mg Tablet

Prescription requiredRx Required

Salt Composition: Eltrombopag Olamine

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

7 Tablets in a Strip

About The Product

Hepatitis C, Hepatitis Medicines, Low Red Platelet Count


Description

Trombopag 50mg Tablet is prescribed by the doctor to treat low platelet counts in specific blood-related conditions. It is mainly given in combination with other medicines to treat a particular condition or increase effectiveness.

Trombopag 50mg contains Eltrombopag that promotes the proliferation and differentiation of megakaryocytes, leading to increased platelet formation and reduced bleeding risk in conditions like chronic ITP, hepatitis C-related thrombocytopenia, or severe aplastic anemia. Take it exactly as prescribed by the doctor.​

Uses

  • Chronic idiopathic thrombocytopenia
  • Severe Aplastic Anemia
  • Low platelet count due to ITP or HCV infection

Side Effects

Trombopag 50mg can cause multiple side effects, most of which are mild to moderate and often temporary. Patients are advised to inform their healthcare provider immediately if symptoms stays for prolonged period of time.

  • Headache
  • Nausea
  • Tiredness
  • Diarrhea
  • Insomnia
  • Dizziness
  • Loss of Appetite
  • Rashes
  • Muscle Pain
  • Fever
  • Chills
  • Allergic Reaction
  • Liver Problem
  • Blood Clots
  • Allergic Reaction

How To Use

  • The usual dose of Trombopag 50mg is one tablet daily. It should be taken on an empty stomach, at the same time each day for consistent blood levels. Consult your doctor for individual dosage as it may vary person to person based on its stage and overall health.
  • Tablet is taken orally with the help of water. Avoid breaking, chewing, biting and crushing of tablet to maintain the medication efficacy.​​

How It Works

  • Trombopag 50mg Tablet contains Eltrombopag, Eltrombopag binds to and activates the trans-membrane domain of the TPO receptor (c-Mpl) on megakaryocyte progenitors in the bone marrow, triggering signaling pathways.
  • This promotes the proliferation and differentiation of megakaryocytes, leading to increased platelet formation and reduced bleeding risk in conditions like chronic ITP, hepatitis C-related thrombocytopenia, or severe aplastic anemia.​​

Safety Advice

Alcohol
Avoid the consumption of alcohol while taking Trombopag 50mg Tablet, as alcohol can decrease the effectiveness of the medicine as well as worsen the symptoms
Pregnancy
Do not take Trombopag 50mg Tablet without consulting the doctor in case of pregnancy, as it can be unsafe to take it during this period.
Breast Feeding
Do not take Trombopag 50mg Tablet without consulting the doctor in case of pregnancy, as it can be unsafe to take it during this period.
Driving
Trombopag 50mg Tablet may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving.
Kidney
Share your medical history with the doctor before starting the Trombopag 50mg Tablet. Do not take it without consulting a doctor if you have any kidney related issue.
Liver
Share your medical history with the doctor before starting the Trombopag 50mg Tablet . Do not take it without consulting a doctor if you have any liver related issue

FAQs

Trombopag 50mg Tablet is used to treat low platelet counts in specific blood-related conditions.

References

  • Lum, S. H., & Grainger, J. D. (2016). Eltrombopag for the treatment of aplastic anemia: current perspectives. Drug Design, Development and Therapy, 2833-2843. https://pubmed.ncbi.nlm.nih.gov/27695288/
  • AML, D. I. (2008). Long-term safety and efficacy of oral eltrombopag for the treatment of idiopathic thrombocytopenic purpura (ITP). Assistant Editors, 93(s1), 379. https://pmc.ncbi.nlm.nih.gov/articles/PMC10614231/
  • Fattizzo, B., Levati, G., Cassin, R., & Barcellini, W. (2019). Eltrombopag in immune thrombocytopenia, aplastic anemia, and myelodysplastic syndrome: from megakaryopoiesis to immunomodulation. Drugs, 79(12), 1305-1319.
  • Dahal, S., Upadhyay, S., Banjade, R., Dhakal, P., Khanal, N., & Bhatt, V. R. (2017). Thrombocytopenia in patients with chronic hepatitis C virus infection. Mediterranean journal of hematology and infectious diseases, 9(1), e2017019. https://pubmed.ncbi.nlm.nih.gov/28293407/
  • Gill, H., Wong, R. S., & Kwong, Y. L. (2017). From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag. Therapeutic advances in hematology, 8(5), 159-174.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Magicine PharmacopyCopyright 2026